ArticleBMC research notes2026
Genomic characterization and comparative analysis of a new Tequatrovirus phage infecting Escherichia coli ST131.
Article in BMC research notes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveThe global rise of antimicrobial resistance with the spread of pathogenic multidrug-resistant clones such as Escherichia coli sequence type (ST) 131 represents a major challenge for public health, renewing interest in bacteriophages as therapeutical agents.
resultsWe report the isolation and characterization of a new bacteriophage, Escherichia phage vB_EcoM-V1EC45, which was isolated from wastewater and was able to infect a clinical E. coli ST131 strain. Its genome is a 170,364 bp double-stranded DNA molecule annotated with 281 coding sequences and 9 tRNAs, including multiple genes involved in antidefense systems. V1EC45 is predicted to harbour a virulent lifestyle. Comparative genomics positioned V1EC45 within the Tequatrovirus genus, and the Tsx outer membrane bacterial protein is predicted to be used as the receptor-binding protein. This work highlights the value of using genomic, structural, and evolutionary analyses to support the directed development of targeted bacteriophage therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.